Ganser A, Ottmann O G, Schulz G, Hoelzer D
Dept. of Hematology, University of Frankfurt, FRG.
Onkologie. 1989 Feb;12(1):13-5. doi: 10.1159/000216589.
In a pilot study, five patients with myelodysplastic syndromes with an excess of blast cells were treated with a combination of recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) and low-dose cytosine-arabinoside (ara-C) in an attempt to selectively kill the leukemic blast cells and thereby to restore normal hemopoiesis. The treatment schedule consisted of three 14-day-cycles of 250 micrograms/m2 rhGM-CSF and 20 mg/m2 ara-C given daily s.c. with four-week treatment-free intervals. In all four evaluable patients the percentage of bone marrow blast cells decreased significantly with an increase in the mature myeloid cells but without bone marrow aplasia. Toxic side effects attributable to the drugs were minor with fever, mild bone pain, erythema and itching at the site of subcutaneous injection of rhGM-CSF. In conclusion, the combined therapy of rhGM-CSF and low-dose ara-C appears to be effective in the short-term control of the leukemic cell population.
在一项初步研究中，对5例原始细胞增多的骨髓增生异常综合征患者，采用重组人粒细胞-巨噬细胞集落刺激因子（rhGM-CSF）与小剂量阿糖胞苷（ara-C）联合治疗，试图选择性地杀伤白血病原始细胞，从而恢复正常造血。治疗方案包括三个14天周期，每天皮下注射250μg/m² rhGM-CSF和20mg/m² ara-C，治疗间隔为四周。在所有4例可评估的患者中，骨髓原始细胞百分比显著下降，成熟髓系细胞增加，但未出现骨髓再生障碍。药物所致的毒性副作用较小，表现为发热、轻度骨痛、rhGM-CSF皮下注射部位出现红斑和瘙痒。总之，rhGM-CSF与小剂量ara-C联合治疗似乎对白血病细胞群的短期控制有效。
